Erratum: Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis? (Nature Clinical Practice Rheumatology (2007) vol. 3 (378-379) 10.1038/ncprheum0530);Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis? Commentary

Nature Clinical Practice Rheumatology

Volumn 3, Issue 7, 2007, Pages 378-379

  Black, Dennis M ^a   Rosen, Clifford J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JOSEPH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID;

CLAVICLE FRACTURE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; INCIDENCE; LEG FRACTURE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PELVIS FRACTURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; TREATMENT OUTCOME; WRIST FRACTURE;

EID: 34447129023     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0563     Document Type: Erratum

References (4)

1. Rossouw JE et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 321-333
2. McNeil C (2007) Breast cancer decline mirrors fall in hormone use, spurs both debate and research. J Natl Cancer Inst 99: 266-267
3. Cumming RG et al. (1997) Calcium intake and fracture risk: Results from the study of osteoporotic fractures. Am J Epidemiol 145 926-934
4. Cranney A et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570-578